Literature DB >> 21304401

Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.

Hua Zhang1, Yongzhi Cui, Nga Voong, Marianna Sabatino, Dave F Stroncek, Sebastien Morisot, Curt I Civin, Alan S Wayne, Bruce L Levine, Crystal L Mackall.   

Abstract

Natural killer (NK) cells can mediate potent antitumor effects, but factors regulating the efficiency of tumor lysis remain unclear. Studies in allogeneic stem cell transplantation highlight an important role for killer cell immunoglobulin-like receptor (KIR) mismatch in overcoming human leukocyte antigen-mediated inhibitory signals. However, other activating and inhibitory signals also modulate tumor lysis by NK cells. We used rhIL15 and artificial antigen presenting cells expressing CD137L and IL15Rα to activate and expand peripheral blood NK cells (CD137L/IL15 NK) up to 1000-fold in 3 weeks. Compared with resting NK cells, CD137L/IL15 NK cells show modest increases in KIR expression and substantial increases in NKG2D, tumor necrosis factor-related apoptosis-inducing ligand, and natural cytotoxicity receptors (NCRs: NKp30, NKp44, NKp46). Compared with resting NK cells, CD137L/IL15 NK cells mediate enhanced cytotoxicity against allogeneic and autologous tumors and KIR signaling did not substantially inhibit cytotoxicity. Rather, tumor lysis by CD137L/IL15 activated NK cells was predominantly driven by NCR signaling as blockade of NCRs dramatically diminished the lysis of a wide array of tumor targets. Furthermore, tumor lysis by CD137L/IL15 NK cells was tightly linked to NCR expression levels that peaked on day 8 to 10 after NK activation, and cytotoxicity diminished on subsequent days as NCR expression declined. We conclude that KIR mismatch is not a prerequisite for tumor killing by CD137L/IL15 NK cells and that NCR expression provides a biomarker for predicting potency of CD137L/IL15 NK cells in studies of NK cell-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21304401      PMCID: PMC3128544          DOI: 10.1097/CJI.0b013e31820d2a21

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  44 in total

Review 1.  NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.

Authors:  A B Bakker; J Wu; J H Phillips; L L Lanier
Journal:  Hum Immunol       Date:  2000-01       Impact factor: 2.850

Review 2.  Immune inhibitory receptors.

Authors:  J V Ravetch; L L Lanier
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

3.  Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells.

Authors:  C Cantoni; C Bottino; R Augugliaro; L Morelli; E Marcenaro; R Castriconi; M Vitale; D Pende; S Sivori; R Millo; R Biassoni; L Moretta; A Moretta
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

4.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.

Authors:  A Diefenbach; E R Jensen; A M Jamieson; D H Raulet
Journal:  Nature       Date:  2001-09-13       Impact factor: 49.962

5.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

6.  Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo.

Authors:  C Y Koh; B R Blazar; T George; L A Welniak; C M Capitini; A Raziuddin; W J Murphy; M Bennett
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

7.  CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

Authors:  Tina Baessler; Jean Enno Charton; Benjamin Joachim Schmiedel; Frank Grünebach; Matthias Krusch; Alexander Wacker; Hans-Georg Rammensee; Helmut Rainer Salih
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

8.  KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

Authors:  Jeffrey M Venstrom; Junting Zheng; Nabila Noor; Karen E Danis; Alice W Yeh; Irene Y Cheung; Bo Dupont; Richard J O'Reilly; Nai-Kong V Cheung; Katharine C Hsu
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

9.  Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.

Authors:  Andreas Lundqvist; Hisayuki Yokoyama; Aleah Smith; Maria Berg; Richard Childs
Journal:  Blood       Date:  2009-02-06       Impact factor: 22.113

10.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

View more
  22 in total

Review 1.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

Review 2.  Umbilical cord blood graft engineering: challenges and opportunities.

Authors:  P A Thompson; K Rezvani; C M Hosing; B Oran; A L Olson; U R Popat; A M Alousi; N D Shah; S Parmar; C Bollard; P Hanley; P Kebriaei; L Cooper; J Kellner; I K McNiece; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 3.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

Review 4.  Immune-based therapies for childhood cancer.

Authors:  Crystal L Mackall; Melinda S Merchant; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2014-10-28       Impact factor: 66.675

5.  Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

Authors:  Nirali N Shah; Kristin Baird; Cynthia P Delbrook; Thomas A Fleisher; Mark E Kohler; Shakuntala Rampertaap; Kimberly Lemberg; Carolyn K Hurley; David E Kleiner; Melinda S Merchant; Stefania Pittaluga; Marianna Sabatino; David F Stroncek; Alan S Wayne; Hua Zhang; Terry J Fry; Crystal L Mackall
Journal:  Blood       Date:  2014-12-01       Impact factor: 22.113

Review 6.  Bringing natural killer cells to the clinic: ex vivo manipulation.

Authors:  Richard W Childs; Maria Berg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

Review 7.  NK cell-based immunotherapies in Pediatric Oncology.

Authors:  Kimberly A McDowell; Jacquelyn A Hank; Kenneth B DeSantes; Christian M Capitini; Mario Otto; Paul M Sondel
Journal:  J Pediatr Hematol Oncol       Date:  2015-03       Impact factor: 1.289

Review 8.  NK cells: immune cross-talk and therapeutic implications.

Authors:  Anshu Malhotra; Anil Shanker
Journal:  Immunotherapy       Date:  2011-10       Impact factor: 4.196

9.  Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Authors:  Yin Liu; Hong-Wei Wu; Michael A Sheard; Richard Sposto; Srinivas S Somanchi; Laurence J N Cooper; Dean A Lee; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2013-02-01       Impact factor: 12.531

10.  CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.

Authors:  Julia A Wagner; Maximillian Rosario; Rizwan Romee; Melissa M Berrien-Elliott; Stephanie E Schneider; Jeffrey W Leong; Ryan P Sullivan; Brea A Jewell; Michelle Becker-Hapak; Timothy Schappe; Sara Abdel-Latif; Aaron R Ireland; Devika Jaishankar; Justin A King; Ravi Vij; Dennis Clement; Jodie Goodridge; Karl-Johan Malmberg; Hing C Wong; Todd A Fehniger
Journal:  J Clin Invest       Date:  2017-10-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.